Riboxin – a derivative (nucleoside) of purine – a precursor of adenosine diphosphate ATP. Refers to a group of drugs that stimulate metabolic processes.
It has antihypoxic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative renal ischemia. It takes a direct part in the metabolism of glucose and promotes the activation of metabolism in conditions of hypoxia and in the absence of ATP.
It activates the metabolism of pyruvic acid to ensure the normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase.
Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle. Penetrating into cells, it has a positive effect on metabolic processes in the myocardium – it increases the strength of heart contractions and promotes more complete relaxation of the myocardium in diastole, resulting in an increase in stroke volume.
The mechanism of antiarrhythmic action is not fully understood.
Reduces platelet aggregation, activates tissue regeneration (especially myocardium and gastrointestinal mucosa).
Clinically significant interaction of Riboxin with drugs from other groups has not been described.
How to take, course of administration and dosage